Table I.

Phase I dose-escalation scheme.

Dose level	Obatoclax dose	Bortezomib dose*
1	30 mg	1.0 mg/m2
2†	30 mg	1.3 mg/m2
3†	45 mg	1.3 mg/m2

^*Bortezomib was administered after obatoclax.

^†If dose-limiting toxicity (DLT) was attributable to myelosuppression and peripheral neuropathy, the dose level was repeated with bortezomib dose reduced to 1.0 mg/m². Dose escalation of obatoclax was permitted to continue if DLT did not recur at the reduced bortezomib dose. A second dose reduction of bortezomib to 0.75 mg/m² was permitted if peripheral neuropathy persisted after initial dose reduction.